Loading
A phase 2/3 trial of Everolimus in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors is a phase 2/3 interventional study registered as NCT07165886 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 298 participants planned, started 2025-08-29 and due to reach its primary completion in 2028-08-29. Interventions recorded: Sirolimus for injection (albumin bound), Octreotide long-acting injection and Everolimus.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares CSPC Pharmaceutical Group, Small-molecule kinase inhibitors and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/